GB9501841D0
(en)
*
|
1995-01-31 |
1995-03-22 |
Co Ordinated Drug Dev |
Improvements in and relating to carrier particles for use in dry powder inhalers
|
GB9515182D0
(en)
*
|
1995-07-24 |
1995-09-20 |
Co Ordinated Drug Dev |
Improvements in and relating to powders for use in dry powder inhalers
|
GB9703673D0
(en)
*
|
1997-02-21 |
1997-04-09 |
Bradford Particle Design Ltd |
Method and apparatus for the formation of particles
|
US20070212422A1
(en)
*
|
1999-11-10 |
2007-09-13 |
Manfred Keller |
Dry powder for inhalation
|
US20060171899A1
(en)
*
|
1998-12-10 |
2006-08-03 |
Akwete Adjei |
Water-stabilized aerosol formulation system and method of making
|
IT1309592B1
(it)
*
|
1999-03-05 |
2002-01-24 |
Chiesi Farma Spa |
Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
|
SK286981B6
(sk)
*
|
1999-03-05 |
2009-08-06 |
Chiesi Farmaceutici S.P.A. |
Prášok na použitie v inhalátore na suché prášky, nosič na tento prášok a spôsob výroby prášku
|
PE20011227A1
(es)
*
|
2000-04-17 |
2002-01-07 |
Chiesi Farma Spa |
Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
|
GB0009468D0
(en)
*
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formulations for use in inhaler devices
|
GB0009469D0
(en)
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formalities for use in inhaler devices
|
GB0012260D0
(en)
|
2000-05-19 |
2000-07-12 |
Astrazeneca Ab |
Novel composition
|
GB0012261D0
(en)
|
2000-05-19 |
2000-07-12 |
Astrazeneca Ab |
Novel process
|
ES2632461T3
(es)
|
2000-06-27 |
2017-09-13 |
Vectura Limited |
Formulaciones para su uso en dispositivos inhaladores
|
GB0027357D0
(en)
|
2000-11-09 |
2000-12-27 |
Bradford Particle Design Plc |
Particle formation methods and their products
|
EP1920763B2
(de)
|
2000-11-30 |
2022-06-15 |
Vectura Limited |
Pharmazeutische Zusammensetzungen zur Inhalation
|
EP2168571B1
(de)
*
|
2000-11-30 |
2018-08-22 |
Vectura Limited |
Inhalierbare Arzneizusammensetzung
|
EP1337241B1
(de)
†
|
2000-11-30 |
2008-01-02 |
Vectura Limited |
Verfahren zur vorbereitung von mikropartikeln zur verwendung in pharmazeutischen zusammensetzungen zur inhalation
|
WO2002056948A1
(en)
|
2001-01-17 |
2002-07-25 |
Vectura Limited |
An inhaler device
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
AU2002333644A1
(en)
|
2001-09-17 |
2003-04-01 |
Glaxo Group Limited |
Dry powder medicament formulations
|
US7931533B2
(en)
|
2001-09-28 |
2011-04-26 |
Igt |
Game development architecture that decouples the game logic from the graphics logics
|
SE0200312D0
(sv)
*
|
2002-02-01 |
2002-02-01 |
Astrazeneca Ab |
Novel composition
|
US20050191357A1
(en)
*
|
2002-03-20 |
2005-09-01 |
Yoshiaki Kawashima |
Method of manufacturing chemical-containing composite particles
|
FI116657B
(fi)
*
|
2002-03-28 |
2006-01-31 |
Focus Inhalation Oy |
Menetelmä kantoainehiukkasten käsittelemiseksi ja niiden käyttö
|
US20030235538A1
(en)
*
|
2002-04-09 |
2003-12-25 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Method for the administration of an anticholinergic by inhalation
|
US7582284B2
(en)
*
|
2002-04-17 |
2009-09-01 |
Nektar Therapeutics |
Particulate materials
|
GB0216562D0
(en)
|
2002-04-25 |
2002-08-28 |
Bradford Particle Design Ltd |
Particulate materials
|
US9339459B2
(en)
|
2003-04-24 |
2016-05-17 |
Nektar Therapeutics |
Particulate materials
|
US8273331B2
(en)
*
|
2002-08-21 |
2012-09-25 |
Norton Healthcare Ltd. |
Inhalation compositions
|
WO2004028545A1
(en)
*
|
2002-09-25 |
2004-04-08 |
Astrazeneca Ab |
A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
EP1452179A1
(de)
*
|
2003-02-27 |
2004-09-01 |
CHIESI FARMACEUTICI S.p.A. |
Neue Kombination von hochwirksamer langzeitiger Beta-2-Agonist und einem Corticosteroid
|
JP2006522634A
(ja)
*
|
2003-04-14 |
2006-10-05 |
ベクトゥラ・リミテッド |
投与効率を向上させるデバイス及び製薬組成
|
US20060147389A1
(en)
*
|
2004-04-14 |
2006-07-06 |
Vectura Ltd. |
Devices and pharmaceutical compositions for enhancing dosing efficiency
|
US7094545B2
(en)
|
2003-04-30 |
2006-08-22 |
Ferring Bv |
Pharmaceutical composition as solid dosage form and method for manufacturing thereof
|
EP1646370A1
(de)
*
|
2003-07-11 |
2006-04-19 |
Glaxo Group Limited |
Pharmazeutische formulierungen
|
WO2005004845A1
(en)
*
|
2003-07-11 |
2005-01-20 |
Glaxo Group Limited |
Pharmaceutical formulations comprising magnesium stearate
|
DK1500390T3
(da)
|
2003-07-25 |
2005-09-19 |
Ferring Bv |
Farmaceutisk præparat som fast dosisform og fremgangsmåde til fremstilling deraf
|
CN1826099B
(zh)
*
|
2003-07-25 |
2010-06-09 |
凡林有限公司 |
固体剂型药物组合物及其制造方法
|
GB0321607D0
(en)
*
|
2003-09-15 |
2003-10-15 |
Vectura Ltd |
Manufacture of pharmaceutical compositions
|
GB0327723D0
(en)
*
|
2003-09-15 |
2003-12-31 |
Vectura Ltd |
Pharmaceutical compositions
|
US20060292081A1
(en)
*
|
2003-09-15 |
2006-12-28 |
Vectura Limited |
Methods for preparing pharmaceutical compositions
|
GB0324918D0
(en)
*
|
2003-10-24 |
2003-11-26 |
Glaxo Group Ltd |
Composition
|
GB0326632D0
(en)
*
|
2003-11-14 |
2003-12-17 |
Jagotec Ag |
Dry powder formulations
|
EP1691782A1
(de)
*
|
2003-12-03 |
2006-08-23 |
Microdrug AG |
Medizinisches präparat mit tiotropium
|
SE0303270L
(sv)
*
|
2003-12-03 |
2005-06-04 |
Microdrug Ag |
Metod för administration av tiotropium
|
SE0303570L
(sv)
*
|
2003-12-03 |
2005-06-04 |
Microdrug Ag |
Fukt-känslig medicinsk produkt
|
SE0303571D0
(sv)
*
|
2003-12-03 |
2003-12-22 |
Microdrug Ag |
Medical product for moisture-sensitive medicaments
|
SE0303569L
(sv)
*
|
2003-12-03 |
2005-06-04 |
Microdrug Ag |
DPI för avlämning av fuktkänsliga medikament
|
SE0303269L
(sv)
*
|
2003-12-03 |
2005-06-04 |
Microdrug Ag |
Medicinsk produkt
|
US7018653B2
(en)
|
2003-12-29 |
2006-03-28 |
Ferring B.V. |
Method for preparing solid dosage form of desmopressin
|
JO3102B1
(ar)
*
|
2004-03-17 |
2017-09-20 |
Chiesi Framaceutici S P A |
صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
|
CN101098678A
(zh)
*
|
2004-04-23 |
2008-01-02 |
锡德克斯公司 |
含有磺基烷基醚环糊精的dpi制剂
|
GB0409703D0
(en)
|
2004-04-30 |
2004-06-02 |
Vectura Ltd |
Pharmaceutical compositions
|
GB0425758D0
(en)
|
2004-11-23 |
2004-12-22 |
Vectura Ltd |
Preparation of pharmaceutical compositions
|
GB0426301D0
(en)
*
|
2004-11-30 |
2004-12-29 |
Vectura Ltd |
Pharmaceutical formulations
|
EP1848444B1
(de)
|
2005-02-10 |
2016-11-09 |
Glaxo Group Limited |
Verfahren zur herstellung von lactose unter verwendung von vorklassifizierungsverfahren sowie damit erzeugte pharmazeutische formulierungen
|
RU2007137121A
(ru)
*
|
2005-03-09 |
2009-04-20 |
Оно Фармасьютикал Ко., Лтд. (Jp) |
Частица и препарат, содержащий указанную частицу
|
JP2008534611A
(ja)
*
|
2005-03-30 |
2008-08-28 |
シェーリング コーポレイション |
抗コリン作用薬、コルチコステロイドおよび長時間作用性βアゴニストを合わせる薬物および方法
|
TWI274641B
(en)
*
|
2005-08-30 |
2007-03-01 |
Rexon Ind Corp Ltd |
Cutting machine
|
US7629331B2
(en)
|
2005-10-26 |
2009-12-08 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
GB0525254D0
(en)
|
2005-12-12 |
2006-01-18 |
Jagotec Ag |
Powder compositions for inhalation
|
GB0613161D0
(en)
*
|
2006-06-30 |
2006-08-09 |
Novartis Ag |
Organic Compounds
|
GB0622818D0
(en)
*
|
2006-11-15 |
2006-12-27 |
Jagotec Ag |
Improvements in or relating to organic compounds
|
EP1944018A1
(de)
*
|
2007-01-10 |
2008-07-16 |
CHIESI FARMACEUTICI S.p.A. |
Mikronisierte Partikel mit niedrigdosierten Wirkstoffen für Pulverzubereitungen zur Inhalation
|
KR20090129998A
(ko)
|
2007-02-11 |
2009-12-17 |
맵 파마슈티컬스, 인코포레이티드 |
부작용 프로파일을 최소화하면서 편두통의 빠른 완화를 가능하게 하는 dhe의 치료적 투여 방법
|
WO2009015037A2
(en)
|
2007-07-21 |
2009-01-29 |
Albany Molecular Research, Inc. |
5-pyridinone substituted indazoles
|
EP2674417A3
(de)
|
2007-11-21 |
2014-04-09 |
Decode Genetics EHF |
Biaryl-PDE4-Inhibitoren zur Behandlung von Entzündungen
|
WO2009088054A1
(ja)
|
2008-01-11 |
2009-07-16 |
Astellas Pharma Inc. |
精巣の疼痛又は不快感行動及び頻尿併発モデル動物
|
JP5501251B2
(ja)
|
2008-01-11 |
2014-05-21 |
アルバニー モレキュラー リサーチ, インコーポレイテッド |
Mch拮抗薬としての(1−アジノン)置換ピリドインドール類
|
EP2080508A1
(de)
|
2008-01-15 |
2009-07-22 |
CHIESI FARMACEUTICI S.p.A. |
Trockenpulverformulierung mit einem anticholinergischen Arzneimittel
|
WO2010059836A1
(en)
|
2008-11-20 |
2010-05-27 |
Decode Genetics Ehf |
Substituted aza-bridged bicyclics for cardiovascular and cns disease
|
EP2191821A1
(de)
*
|
2008-11-26 |
2010-06-02 |
CHIESI FARMACEUTICI S.p.A. |
Mikropartikel enthaltend ein Salz von 8-Hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone mit verbesserten Adhesionseigenschaften zur Trockenpulver-Inhalation
|
BRPI1007350B8
(pt)
|
2009-01-26 |
2021-05-25 |
Israel Institute For Biological Res |
compostos espiro heterocíclicos bicíclicos
|
US9925282B2
(en)
|
2009-01-29 |
2018-03-27 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
WO2010097188A1
(en)
*
|
2009-02-25 |
2010-09-02 |
Chiesi Farmaceutici S.P.A. |
Inhalation particles comprising a salt of carmoterol and a corticosteroid
|
DK2400950T3
(da)
|
2009-02-26 |
2019-07-29 |
Glaxo Group Ltd |
Farmaceutiske formuleringer omfattende 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
|
US20120101077A1
(en)
*
|
2009-04-24 |
2012-04-26 |
Schering Corporation |
Agglomerate formulations useful in dry powder inhalers
|
WO2011015289A1
(en)
|
2009-08-04 |
2011-02-10 |
Chiesi Farmaceutici S.P.A. |
8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate
|
GB0918249D0
(en)
|
2009-10-19 |
2009-12-02 |
Respivert Ltd |
Compounds
|
GB0921075D0
(en)
|
2009-12-01 |
2010-01-13 |
Glaxo Group Ltd |
Novel combination of the therapeutic agents
|
EP2360147A1
(de)
|
2010-02-22 |
2011-08-24 |
CHIESI FARMACEUTICI S.p.A. |
Verfahren zur Herstellung von kristallinen Partikeln von einem Salz von 8-Hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-chinolinon (Carmoterol)
|
WO2011120779A1
(en)
|
2010-04-01 |
2011-10-06 |
Chiesi Farmaceutici S.P.A. |
Process for preparing carrier particles for dry powders for inhalation
|
SI2560611T1
(en)
*
|
2010-04-21 |
2018-03-30 |
Chiesi Farmaceutici S.P.A. |
A process for preparing particles with reduced electrostatic charges
|
NZ629829A
(en)
|
2010-04-30 |
2015-11-27 |
Alexion Pharma Inc |
Anti-c5a antibodies and methods for using the antibodies
|
US9259376B2
(en)
|
2010-06-03 |
2016-02-16 |
Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. |
Process for dry powder formulations
|
EA201291306A1
(ru)
*
|
2010-06-22 |
2013-05-30 |
КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. |
Состав сухого порошка, содержащий антимускариновое средство
|
EA027692B1
(ru)
*
|
2010-08-03 |
2017-08-31 |
КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. |
Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы
|
EP2611416B1
(de)
*
|
2010-09-03 |
2015-08-19 |
Pharmaterials Ltd. |
Pharmazeutische zubereitung zur verwendung in pulverinhalatoren
|
MX354828B
(es)
|
2010-09-29 |
2018-03-22 |
Pulmatrix Operating Co Inc |
Polvos secos de cationes metálicos monovalentes para inhalación.
|
WO2012041717A1
(en)
|
2010-09-30 |
2012-04-05 |
Chiesi Farmaceutici S.P.A. |
Use of magnesium stearate in dry powder formulations for inhalation
|
UY33337A
(es)
|
2010-10-18 |
2011-10-31 |
Respivert Ltd |
DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
|
MX350838B
(es)
|
2011-02-11 |
2017-09-18 |
Grain Proc Corporation * |
Composicion de sal.
|
TR201205852A2
(tr)
*
|
2011-06-02 |
2012-12-21 |
Bi̇lgi̇ç Mahmut |
Geliştirilmiş yeni kuru toz formülasyonu.
|
TR201105367A2
(tr)
*
|
2011-06-02 |
2012-12-21 |
Bi̇lgi̇ç Mahmut |
Akış özellikleri geliştirilmiş bir kuru toz formülasyonu.
|
WO2013109208A1
(en)
*
|
2012-01-16 |
2013-07-25 |
Mahmut Bilgic |
Formulations comprising formoterol as active agent
|
WO2013109211A1
(en)
*
|
2012-01-16 |
2013-07-25 |
Mahmut Bilgic |
Dry powder formulations comprising r-formoterol as active agent
|
WO2013109214A1
(en)
*
|
2012-01-16 |
2013-07-25 |
Mahmut Bilgic |
Process for the preparation of dry powder formulations
|
HRP20230147T1
(hr)
*
|
2012-01-25 |
2023-03-31 |
Chiesi Farmaceutici S.P.A. |
Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom
|
WO2013114371A1
(en)
|
2012-02-01 |
2013-08-08 |
Protalix Ltd. |
Dry powder formulations of dnase i
|
CN107596518B
(zh)
|
2012-02-29 |
2021-04-23 |
普马特里克斯营业公司 |
可吸入干粉剂
|
NZ628072A
(en)
|
2012-03-13 |
2015-08-28 |
Respivert Ltd |
Crystalline pi3 kinase inhibitors
|
JP6267685B2
(ja)
|
2012-04-13 |
2018-01-24 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
集合粒子
|
US10105316B2
(en)
|
2012-07-05 |
2018-10-23 |
Arven llac Sanayi Ve Ticaret A.S. |
Inhalation compositions comprising muscarinic receptor antagonist
|
WO2014007772A2
(en)
*
|
2012-07-05 |
2014-01-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Inhalation compositions comprising glucose anhydrous
|
JP6499077B2
(ja)
|
2012-10-25 |
2019-04-10 |
ザ ジェネラル ホスピタル コーポレイション |
アルツハイマー病と関連疾患の治療のための併用療法
|
US11052202B2
(en)
|
2012-11-07 |
2021-07-06 |
Chiesi Farmaceutici S.P.A. |
Drug delivery device for the treatment of patients with respiratory diseases
|
US9757395B2
(en)
|
2012-12-20 |
2017-09-12 |
Otitopic Inc. |
Dry powder inhaler and methods of use
|
US9757529B2
(en)
|
2012-12-20 |
2017-09-12 |
Otitopic Inc. |
Dry powder inhaler and methods of use
|
US9649302B2
(en)
|
2013-01-28 |
2017-05-16 |
Incozen Therapeutics Pvt. Ltd. |
Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast N-oxide
|
GB201305825D0
(en)
|
2013-03-28 |
2013-05-15 |
Vectura Ltd |
New use
|
ES2768648T3
(es)
|
2013-03-29 |
2020-06-23 |
Alexion Pharma Inc |
Composiciones y métodos para aumentar la semivida en suero de un agente terapéutico dirigido a C5 del complemento
|
CN105473133A
(zh)
|
2013-04-30 |
2016-04-06 |
欧缇托匹克公司 |
干粉制剂及使用方法
|
US10525005B2
(en)
|
2013-05-23 |
2020-01-07 |
The General Hospital Corporation |
Cromolyn compositions and methods thereof
|
TR201802969T4
(tr)
*
|
2013-07-01 |
2018-03-21 |
Arven Ilac Sanayi Ve Ticaret Anonim Sirketi |
Yeni inhalasyon formülasyonları.
|
HUE053957T2
(hu)
*
|
2013-07-11 |
2021-08-30 |
Chiesi Farm Spa |
Antikolinerg, kortikoszteroid és béta-adrenerg anyagot tartalmazó száraz porkészítmény inhalálással történõ beadásra
|
EP3052092A2
(de)
*
|
2013-10-02 |
2016-08-10 |
Vectura Limited |
Verfahren und vorrichtung
|
US9427376B2
(en)
|
2013-10-10 |
2016-08-30 |
Chiesi Farmaceutici S.P.A. |
Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
|
JP2016534063A
(ja)
|
2013-10-22 |
2016-11-04 |
ザ ジェネラル ホスピタル コーポレイション |
クロモリン誘導体ならびに関連するイメージングおよび治療方法
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
US9554992B2
(en)
|
2014-06-09 |
2017-01-31 |
Chiesi Farmaceutici S.P.A. |
Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
|
EP2957552B1
(de)
|
2014-06-16 |
2020-01-22 |
Arven Ilac Sanayi Ve Ticaret A.S. |
Vilanterolformulierungen
|
TR201407010A2
(tr)
|
2014-06-16 |
2015-12-21 |
Arven Ilac Sanayi Ve Ticaret Anonim Sirketi |
Vilanterol formülasyonları.
|
WO2016005443A1
(en)
*
|
2014-07-09 |
2016-01-14 |
Arven Ilac Sanayi Ve Ticaret A.S. |
A process for the preparation of formulations for inhalation
|
WO2016057693A1
(en)
|
2014-10-10 |
2016-04-14 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
MX2017005692A
(es)
|
2014-10-31 |
2017-08-07 |
Glaxosmithkline Ip Dev Ltd |
Formulacion en polvo.
|
RU2693201C1
(ru)
*
|
2015-06-23 |
2019-07-01 |
Шлюмберже Текнолоджи Б.В. |
Распознание расклинивающего агента с помощью мобильного устройства
|
US11224594B2
(en)
*
|
2015-09-16 |
2022-01-18 |
Philip Morris Products S.A. |
Nicotine formulations and methods of making and using the same
|
JP6942126B2
(ja)
*
|
2015-11-16 |
2021-09-29 |
キエージ・フアルマチエウテイチ・エツセ・ピ・ア |
抗コリン作用薬、コルチコステロイド及びβ−アドレナリン作用薬を含む乾燥粉末製剤の製造方法
|
PT3628331T
(pt)
|
2015-11-16 |
2021-10-20 |
Chiesi Farm Spa |
Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico
|
SG11201805204WA
(en)
|
2015-12-24 |
2018-07-30 |
Philip Morris Products Sa |
Nicotine particle capsule
|
CN109922800B
(zh)
|
2016-08-31 |
2023-06-13 |
通用医疗公司 |
与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
|
CN110612095A
(zh)
*
|
2017-05-11 |
2019-12-24 |
奇斯药制品公司 |
制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法
|
CA3060020A1
(en)
|
2017-05-11 |
2018-11-15 |
Chiesi Farmaceutici S.P.A. |
A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
|
US10583085B2
(en)
*
|
2017-05-17 |
2020-03-10 |
Chiesi Farmaceutici S.P.A. |
Carrier particles for dry powder formulations for inhalation
|
EA202090247A1
(ru)
|
2017-07-14 |
2020-05-12 |
Цитомкс Терапьютикс, Инк. |
Антитела против cd166 и их применения
|
EP3658033A4
(de)
*
|
2017-07-26 |
2021-02-24 |
Shenzhen Xpectvision Technology Co., Ltd. |
System mit einer räumlich ausgedehnten röntgenstrahlenquelle zur röntgenbildgebung
|
US11365241B2
(en)
|
2017-07-27 |
2022-06-21 |
Alexion Pharmaceuticals, Inc. |
High concentration anti-C5 antibody formulations
|
WO2019060604A1
(en)
|
2017-09-20 |
2019-03-28 |
Teva Branded Pharmaceutical Products R&D, Inc. |
INHALABLE MEDICINE
|
WO2019060797A1
(en)
|
2017-09-22 |
2019-03-28 |
Teva Branded Pharmaceutical Products R&D, Inc. |
PROCESS FOR PRODUCING POWDERS FOR INHALING
|
KR20230040375A
(ko)
*
|
2017-09-22 |
2023-03-22 |
오티토픽 인코퍼레이티드 |
스테아르산마그네슘을 갖는 건조 분말 조성물
|
US10786456B2
(en)
|
2017-09-22 |
2020-09-29 |
Otitopic Inc. |
Inhaled aspirin and magnesium to treat inflammation
|
WO2019067708A1
(en)
*
|
2017-09-27 |
2019-04-04 |
Teva Branded Pharmaceutical Products R&D, Inc. |
METHOD FOR DECREASING PARTICLE SIZE
|
AU2019299347A1
(en)
*
|
2018-07-02 |
2021-01-21 |
Aztherapies, Inc. |
Powdered formulations of cromolyn sodium and alpha-lactose
|
BR112021001402A2
(pt)
|
2018-07-27 |
2021-04-27 |
Chiesi Farmaceutici S.P.A. |
novas partículas carreadoras para formulações de pó seco para inalação
|
KR20210042412A
(ko)
|
2018-09-06 |
2021-04-19 |
주식회사 이노파마스크린 |
천식 또는 파킨슨병 치료를 위한 방법 및 조성물
|
JP7368065B2
(ja)
|
2018-10-30 |
2023-10-24 |
キエージィ ファーマチェウティチ エス.ペー.アー. |
人工呼吸器を装着している患者に薬物を投与するための装置
|
BR112021012172A2
(pt)
|
2018-12-12 |
2021-08-31 |
Kite Pharma, Inc. |
Receptores de antígenos quiméricos e de célula t e métodos de uso
|
JP7455144B2
(ja)
|
2019-04-29 |
2024-03-25 |
インスメッド インコーポレイテッド |
トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法
|
AU2020356243A1
(en)
|
2019-09-24 |
2022-03-24 |
Chiesi Farmaceutici S.P.A. |
Novel carrier particles for dry powder formulations for inhalation
|
WO2021217024A1
(en)
|
2020-04-24 |
2021-10-28 |
Millennium Pharmaceuticals, Inc. |
Anti-cd19 antibodies and uses thereof
|
US20230277524A1
(en)
|
2020-05-22 |
2023-09-07 |
Trailhead Biosystems Inc. |
Combination therapy for treatment of viral infections
|
CN112451509B
(zh)
*
|
2020-12-19 |
2023-03-07 |
沈阳药科大学 |
一种川丁特罗吸入粉雾剂及其制备方法
|
CN117425673A
(zh)
|
2021-04-09 |
2024-01-19 |
武田药品工业株式会社 |
靶向补体因子d的抗体和其用途
|
EP4330283A1
(de)
|
2021-04-26 |
2024-03-06 |
Millennium Pharmaceuticals, Inc. |
Anti-adgre2-antikörper und verwendungen davon
|
KR20240004286A
(ko)
|
2021-04-26 |
2024-01-11 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
항 Clec12A 항체 및 이의 용도
|
AU2022372894A1
(en)
|
2021-10-20 |
2024-04-18 |
Takeda Pharmaceutical Company Limited |
Compositions targeting bcma and methods of use thereof
|
WO2023117967A1
(en)
|
2021-12-21 |
2023-06-29 |
Chiesi Farmaceutici S.P.A. |
Dry powder formulations filled in an inhaler with improved resistance to humidity
|
WO2023117985A1
(en)
|
2021-12-21 |
2023-06-29 |
Chiesi Farmaceutici S.P.A. |
Dry powder formulations filled in an inhaler with improved resistance to humidity
|
WO2023150747A1
(en)
|
2022-02-07 |
2023-08-10 |
Insmed Incorporated |
Dry powder compositions of bedaquiline and salts and methods of use thereof
|
WO2024062007A1
(en)
|
2022-09-22 |
2024-03-28 |
Chiesi Farmaceutici S.P.A. |
Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
|